Loading…
Loading…
Healthcare Realty Trust NYSE: HR reported third-quarter results marked by higher occupancy, leasing spreads and same-store net operating income growth, while raising its full-year outlook for the third time in 2026.
Healthcare Realty Trust Incorporated ( HR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Doris Lo - First Vice President of Corporate Finance Peter Scott - President, CEO & Director Robert Hull - Executive VP & COO Daniel Gabbay - Executive VP & CFO Conference Call Participants Richard Anderson - Cantor Fitzgerald & Co., Research Division Michael Stroyeck - Green Street Advisors, LLC, Research Division Omotayo Okusanya - Deutsche Bank AG, Research Division Nicholas Yulico - Scotiabank Global Banking and Markets, Research Division Connor Mitchell - UBS Investment Bank, Research Division Seth Bergey - Citigroup Inc., Research Division Robin Haneland - BMO Capital Markets Equity Research David Rodgers - Raymond James & Associates, Inc., Research Division Austin Wurschmidt - KeyBanc Capital Markets Inc., Research Division Michael Carroll - RBC Capital Markets, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to Healthcare Realty Third Quarter 2026 Earnings Call.
Although the revenue and EPS for Healthcare Realty Trust (HR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Healthcare Realty Trust (HR) came out with quarterly funds from operations (FFO) of $0.42 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to FFO of $0.41 per share a year ago.
NASHVILLE, Tenn., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE:HR) today announced results for the third quarter ended September 30, 2026. In addition, the Company announced an increased 2026 Normalized FFO guidance range of $1.65 to $1.67 per share (diluted), a $0.02 increase at the midpoint from July guidance, and an increased Same Store Cash NOI growth guidance range of 5.00% to 5.25% (+75bps increase at the low end and +25bps at the high end from July guidance).
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim an
Apple just got cut, BlackRock got a lift, and chipmakers are under pressure ahead of a week packed with big-tech earnings. Find out which stocks Wall Street is moving on Tuesday and why the calls matter right now.